Prof Sternberg gives us the latest from the PROSPER study, in which PSA response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) were treated with enzalutamide (ENZA).
Comments:
No comments yet... Be the first!
Post your comment:
Your comment has been sent and is waiting for approval to be displayed.
Your comment cannot be sent. Please try again.
"WebsEdge was a great team to work with. They covered our 101st Annual Meeting and did a great job at capturing the message we wanted to convey to our attendees. Seemless process prior, during and after the meeting."